Glaukos (NYSE:GKOS) Shares Gap Up to $79.95

Glaukos Co. (NYSE:GKOS) gapped up prior to trading on Thursday . The stock had previously closed at $79.95, but opened at $83.15. Glaukos shares last traded at $83.42, with a volume of 515 shares.

GKOS has been the topic of several recent analyst reports. Oppenheimer raised Glaukos from a “market perform” rating to an “outperform” rating and set a $100.00 target price on the stock in a research note on Thursday. Piper Sandler cut Glaukos from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $70.00 to $80.00 in a research note on Friday, January 29th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised Glaukos from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $50.00 to $72.00 in a research report on Wednesday, December 16th. Finally, Smith Barney Citigroup raised Glaukos from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $50.00 to $72.00 in a research report on Wednesday, December 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $66.38.

The company has a 50-day simple moving average of $88.10 and a two-hundred day simple moving average of $72.06. The company has a debt-to-equity ratio of 0.37, a quick ratio of 9.31 and a current ratio of 9.73. The firm has a market capitalization of $3.82 billion, a P/E ratio of -48.45 and a beta of 1.87.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Thursday, February 25th. The medical instruments supplier reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.30. Glaukos had a negative return on equity of 7.99% and a negative net margin of 33.61%. As a group, research analysts forecast that Glaukos Co. will post -1.41 earnings per share for the current fiscal year.

In other news, CFO Joseph E. Gilliam sold 13,750 shares of Glaukos stock in a transaction that occurred on Tuesday, February 9th. The shares were sold at an average price of $96.58, for a total transaction of $1,327,975.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.70% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in GKOS. US Bancorp DE raised its holdings in Glaukos by 137.9% in the 3rd quarter. US Bancorp DE now owns 590 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 342 shares during the last quarter. Strs Ohio raised its holdings in Glaukos by 900.0% in the 3rd quarter. Strs Ohio now owns 1,000 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 900 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in Glaukos in the 1st quarter worth approximately $55,000. Vantage Consulting Group Inc purchased a new position in Glaukos in the 4th quarter worth approximately $74,000. Finally, KBC Group NV purchased a new position in Glaukos in the 4th quarter worth approximately $102,000.

About Glaukos (NYSE:GKOS)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Recommended Story: What defines an oversold asset?

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.